Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson’s Disease: Defining the Preclinical, Clinical and Toxicity Issues

Publisher： Bentham Science Publishers

E-ISSN： 1875-5704|13|8|1205-1221

ISSN： 1567-2018

Source： Current Drug Delivery, Vol.13, Iss.8, 2016-12, pp. : 1205-1221

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tolcapone in Parkinson’s disease: liver toxicity and clinical efficacy

By Borges Nuno

Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. : 69-73

Informa Healthcare

Access to resources Recommend Favorite

Neurotrophic Factors in Parkinson’s Disease: What Have we Learned from Pre-Clinical and Clinical Studies?

Current Medicinal Chemistry, Vol. 25, Iss. 31, 2018-09 ,pp. : 3682-3702

Bentham Science Publishers

Access to resources Recommend Favorite

Implementing NICE clinical guidelines on Parkinson’s disease

By Ryton Beverly A Liddle B Jane

Clinical Medicine, Vol. 9, Iss. 5, 2009-10 ,pp. : 436-440

Royal College Of Physicians

Access to resources Recommend Favorite

A review of pramipexole and its clinical utility in Parkinson’s disease

By Holloway Robert G Biglan Kevin M

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 2, 2002-02 ,pp. : 197-210

Informa Healthcare

Access to resources Recommend Favorite

Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinsons Disease

By Kaakkola S.

Drugs, Vol. 59, Iss. 6, 2000-06 ,pp. : 1233-1250

Adis International

Access to resources Recommend Favorite